Yu et al. further demonstrated that PD-1/PD-L1 inhibitors can activate CD8 + T cells, inducing tumor cells to undergo various forms of RCD, such as ferroptosis, pyroptosis, and necroptosis [174]. Here, CD8A is linked to neoplasm.